Tuesday, November 08, 2022
Bombshell #2 from California Clinicians group: Vaccines Not Helping Against COVID-19 During Omicron Surge
A group of California Central Valley primary care physicians and specialists continue to turn up disturbing findings associated with UK population-wide data, finding disturbing data based on a large, real-world evidence-based population-wide cohort retrospective study covering over 22 million persons in the UK. Like the previous study covered by TrialSite, these practicing clinician-real-world data investigators report bombshell outcomes that demand attention.
At this point, there is trivial difference in outcome between vaccinated and unvaccinated across cases, hospitalizations, and death. The findings run counter to the one-size-fit-all mass vaccination theme that continues to emanate out of English-speaking nations from the UK, USA, Australia, to New Zealand.
Rather, the California-based clinicians report a negative vaccine effectiveness impacted by key variables such as comorbidities, ethnicity, vaccination rates, and other factors. Fundamental to human health at this stage of the pandemic and “irrespective of vaccination” is the need for “uniform screening protocols and protective measures.”
The group attempted to get published with their last study and unfortunately, found few takers, probably due to the fact that the findings diverge from the mainstream health establishment’s narrative. But the group of practicing primary care and specialist physicians continue to generate study outcomes that must be read carefully and understood.
Previous Work
TrialSite showcases previous work by the group in “California Physician-driven Study of UK Population: COVID-19 Cases, Hospitalizations & Deaths Show Fully Vaccinated Elderly at Significant Risk.” This study was also represented by Dr. Emani.
Inquiring and analyzing nationwide data covering confirmed SARS-CoV-2 cases, hospitalizations, and deaths in the UK starting from the beginning of the pandemic to investigate infection patterns, hospitalization, and deaths across various age cohorts during the COVID-19 pandemic, the California-based group probed 22,072,550 cases, 848,911 hospitalizations, and 175,070 deaths due to COVID-19 across the UK. The analysis revealed that 11,315,793 (51.3%) of the cases, 244,708 (28.8%) of hospitalizations, and 28,659 (16.4%) of deaths occurred during the most recent Omicron surge. When comparing the period of February 28-May 1, 2022, with the prior 12-weeks, they observed a significant increase in the case fatality rate (0.19% vs 0.41%; RR 2.11 [2.06-2.16], p<0.001) and odds of hospitalization (1.58% vs 3.72%; RR 2.36[2.34-2.38]; p<0.001). At the same time, a significant increase in cases (23.7% vs 40.3%; RR1.70 [1.70-1.71]; p<0.001) among ≥50 years of age and hospitalizations (39.3% vs 50.3%; RR1.28 [1.27-1.30]; p<0.001) and deaths (67.89% vs 80.07%; RR1.18 [1.16-1.20]; p<0.001) among ≥75 years of age was observed.
Disturbingly, the vaccine effectiveness (VE) for the third dose was in negative since December 20, 2021, with a significantly increased proportion of SARS-CoV2 cases, hospitalizations, and deaths among the vaccinated; and lower proportion of cases, hospitalizations, and deaths among the unvaccinated.
Demonstrating the risks of co-morbidities, pre-existing conditions were present in 95.6% of all COVID-19 deaths. The physician-real-world investigators caution that various ethnicities, comorbidities, deprivation score, and vaccination rate disparities were noted that can adversely affect hospitalization and deaths among compared groups.
Background
Based in Stockton, California. Dr. Ventaka R. Emani recently sent the group’s most recent work to TrialSite that was uploaded to the preprint server medRxiv. Titled “Increasing SARS-CoV2 cases, hospitalizations, and deaths among the vaccinated populations during the Omicron (B.1.1.529) variant surge in UK,” the California group of cardiovascular specialists and primary care doctors were at it again, investigating what is not a popular topic to delve into in mainstream medicine.
In a previous telephone conversation with TrialSite’s founder Daniel O’Connor, Dr. Emani shared that they weren’t sure if their last study would get accepted by any major journals.
The Study
Again, conducting a retrospective observational study, the California team analyzed COVID-19 cases, hospitalizations, and death during the pandemic in the UK. The group also analyzed various variables possibly impacting outcomes from ethnicity to vaccination disparities and co-morbidities in the form of preexisting conditions. Looking at a UK population ranging in age from 18 and up, they studied the period August 16, 2021, through March 27, 2022.
What were the results?
Dr. Emani and team report that toward the end of the Omicron variant-driven surge in the UK running from February 28, to May 1, 2022, they observed a slight rise in the proportion of cases (cases (23.7% vs 40.3%; RR1.70 [1.70-1.71]; p<0.001) and hospitalizations (39.3% vs 50.3%; RR1.28 [1.27-1.30]; p><0.001) among ≥50 years of age, and deaths (67.89% vs 80.07%; RR1.18 [1.16-1.20]; p><0.001) among ≥75 years of age compared to the earlier period (December 6, 2021-February 27, 2022) during the Omicron variant surge. “Using the available data from vaccine surveillance reports, we compared the Omicron variant surge (December 27, 2021-March 20, 2022) with the Delta variant surge (August 16-December 5, 2021). Our comparative analysis shows a significant decline in case fatality rate (all ages [0.21% vs 0.39%; RR 0.54 (0.52-0.55); p><0.001], over 18 years of age [0.25% vs 0.58%; RR 0.44 (0.43-0.45); p><0.001], and over 50 years of age [0.72% vs 1.57%; RR 0.46 (0.45-0.47); P><0.001]) and the risk of ><0.001) and hospitalizations (39.3% vs 50.3%; RR1.28 [1.27-1.30]; p<0.001) among ≥50 years of age, and deaths (67.89% vs 80.07%; RR1.18 [1.16-1.20]; p<0.001) among ≥75 years of age compared to the earlier period (December 6, 2021-February 27, 2022) during the Omicron variant surge.”
The California group embraced vaccine surveillance reports to evaluate the delta between the Omicron variant surge (December 27, 2021-March 20, 2022) with the Delta variant surge (August 16-December 5, 2021).
What does this comparative analysis reveal?
First there was a significant decline in case fatality rate (all ages [0.21% vs 0.39%; RR 0.54 (0.52-0.55); p<0.001] for those persons 18 years of age and up [0.25% vs 0.58%; RR 0.44 (0.43-0.45); p<0.001] and over 50 years of age [0.72% vs 1.57%; RR 0.46 (0.45-0.47); P<0.001]) and the risk of hospitalizations (all ages [0.62% vs 0.99%; RR 0.63 (0.62-0.64); p<0.001], over 18 years and up [0.67% vs 1.38%; RR 0.484 (0.476-0.492); p<0.001], and over 50 years of age [1.45% vs 2.81%; RR 0.52 (0.51-0.53); p<0.001]).
Both the unvaccinated (0.41% vs 0.77%; RR 0.54 (0.51-0.57); p<0.001) and vaccinated (0.25% vs 0.59%; RR 0.43 (0.42-0.44); p<0.001) populations of over 18 years of age showed a significant decline in the case fatality rate during the Omicron variant surge when compared to the Delta variant surge.
What’s the California group’s findings summary?
First, they report, not surprisingly, a marked decline in the risk of hospitalization for both the unvaccinated (1.27% vs 2.92%; RR 0.44 (0.42-0.45); p<0.001) and vaccinated (0.65% vs 1.19%; RR 0.54 (0.53-0.55); p<0.001) populations of over 18 years of age during the same period.
In what could be considered bombshell evidence, the group of doctor’s report that they observed a negative vaccine effectiveness (VE) associated with the third booster dose of the vaccine since December 20, 2021, with a significantly increased proportion of SARS-CoV2 cases, hospitalizations, and deaths among the vaccinated.
Conversely, Dr. Emani and colleagues report a decreased proportion of cases, hospitalizations, and deaths among the unvaccinated.
Much like the last study, the California-based clinicians report that 95.6% of all COVID-19 deaths in the UK are associated with pre-existing conditions. Like before they note the data points to other elements to consider from ethnicity and deprivation score to vaccination rate disparities which can adversely impact key indicators from hospitalization and deaths among the compared groups.
Bombshell Takeaway
Emani et al. again, are attempting to wake up their colleagues with data and science. The team wrote in their conclusion:
“There is no discernable optimal vaccine effectiveness among ≥18 years of age and vaccinated third dose population since the beginning (December 20, 2021) of the Omicron variant surge.” They noted that more specific, granular validation models targeting VE against hospitalization and deaths necessitates the incorporation of other variables mentioned above (e.g., pre-existing conditions, ethnicity, etc.).
In a finding counter to the medical establishment, the authors report that there is little difference in outcome now between vaccinated and unvaccinated in the Omicron period. They declared:
“Both the vaccinated and unvaccinated populations showed favorable outcomes with a significant decline in case fatality rate and risk of hospitalizations during the Omicron variant surge.”
Fundamental to the clinician’s outlook based on the slicing, dicing and analysis of real-world data: the COVID-19 vaccines offer little benefit moving forward in the Omicron period. This directly counters what could be considered a one-size-fit-all message from most health authorities across Anglo-centric societies—whether the UK, the USA, Australia, New Zealand, etc.
Showcasing the necessity of infection prevention targeting higher risk populations (e.g., the elderly) “irrespective of vaccination,” the doctors stress the use of “uniform screening protocols and protective measures.” These clinicians have something profound to say based on the data analysis out of the UK—are health systems., government, and industry listening?
Principal Investigator Point of View
Dr. Emani emailed some of his thoughts on the study to TrialSite:
“As researchers, we have to stay within the scope of our data. All the available evidence suggests that the vaccine effectiveness is suboptimal, and protection is brief during the Omicron variant surge.”
Emani continued:
“Our data also shows that there are no adequate controls to compare the vaccine effectiveness for hospitalization, severe disease, and/or deaths as the unvaccinated population have more comorbidities and risk prone behavior than the vaccinated population.”
In keeping with the data and undoubtedly tapping into the physicians’ real world clinic experience during the pandemic the Manteca, based clinical-scientists shared:
“We recommend that all the risk factors including comorbidities and risk prone behavior should be adjusted at individual level than the population level while calculating VE for the hospitalizations, severe diseases and or deaths through models that should be validated in the same lines as the Randomized Controlled Trials.”
Finally, the group recommends a two-pronged approach to improving pandemic response at this point during the tail end of the pandemic—as Dr. Emani concludes:
“The recommended population (especially elderly with high risk) should get vaccinated per the current health department guidelines, but at the same time, should also take precautions to avoid contracting disease based on the data from our study. We also suggest that nation’s top Health policy bodies should look at all the emerging data carefully and come up with guidelines to protect public.”
****************************************************
Also see my other blogs. Main ones below:
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com (AUSTRALIAN POLITICS)
http://snorphty.blogspot.com (TONGUE-TIED)
https://immigwatch.blogspot.com (IMMIGRATION WATCH)
https://awesternheart.blogspot.com (THE PSYCHOLOGIST)
http://jonjayray.com/blogall.html More blogs
**************************************************
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment